GSK: GSK's severe asthma drug depemokimab denied orphan drug designation in Korea

GlaxoSmithKline (GSK)'s investigational treatment for severe eosinophilic asthma, depemokimab, has encountered its first regulatory setback in Korea.The company's strategy to introduce the drug through orphan drug designation (ODD) has failed, making it likely that GSK will need to revise its regula